CN108929336A - 作为nmda受体活性的调节剂的噻唑并嘧啶酮类 - Google Patents

作为nmda受体活性的调节剂的噻唑并嘧啶酮类 Download PDF

Info

Publication number
CN108929336A
CN108929336A CN201810852075.0A CN201810852075A CN108929336A CN 108929336 A CN108929336 A CN 108929336A CN 201810852075 A CN201810852075 A CN 201810852075A CN 108929336 A CN108929336 A CN 108929336A
Authority
CN
China
Prior art keywords
methyl
compound
alkyl
ethyl
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810852075.0A
Other languages
English (en)
Chinese (zh)
Inventor
于江
吴国胜
袁步伟
伊莱沙·维尔缪
雅各布·施瓦茨
C·李
本杰明·塞勒斯
马修·沃尔格拉夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN108929336A publication Critical patent/CN108929336A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201810852075.0A 2013-10-11 2014-10-08 作为nmda受体活性的调节剂的噻唑并嘧啶酮类 Pending CN108929336A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/085031 2013-10-11
CN2013085031 2013-10-11
CNPCT/CN2014/085959 2014-09-05
CN2014085959 2014-09-05
CN201480055668.4A CN105612162B (zh) 2013-10-11 2014-10-08 作为nmda受体活性的调节剂的噻唑并嘧啶酮类

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480055668.4A Division CN105612162B (zh) 2013-10-11 2014-10-08 作为nmda受体活性的调节剂的噻唑并嘧啶酮类

Publications (1)

Publication Number Publication Date
CN108929336A true CN108929336A (zh) 2018-12-04

Family

ID=51688060

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810852075.0A Pending CN108929336A (zh) 2013-10-11 2014-10-08 作为nmda受体活性的调节剂的噻唑并嘧啶酮类
CN201480055668.4A Active CN105612162B (zh) 2013-10-11 2014-10-08 作为nmda受体活性的调节剂的噻唑并嘧啶酮类

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480055668.4A Active CN105612162B (zh) 2013-10-11 2014-10-08 作为nmda受体活性的调节剂的噻唑并嘧啶酮类

Country Status (19)

Country Link
US (2) US9988400B2 (enExample)
EP (2) EP3055315B1 (enExample)
JP (2) JP6419800B2 (enExample)
KR (1) KR102361108B1 (enExample)
CN (2) CN108929336A (enExample)
BR (1) BR112016007563B1 (enExample)
CA (1) CA2926830C (enExample)
DK (1) DK3055315T3 (enExample)
ES (1) ES2690355T3 (enExample)
HR (1) HRP20181596T1 (enExample)
HU (1) HUE040651T2 (enExample)
LT (1) LT3055315T (enExample)
MX (1) MX2016004540A (enExample)
PL (1) PL3055315T3 (enExample)
PT (1) PT3055315T (enExample)
RS (1) RS58047B1 (enExample)
RU (1) RU2703273C2 (enExample)
SI (1) SI3055315T1 (enExample)
WO (1) WO2015052226A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112094267A (zh) * 2020-08-14 2020-12-18 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 1-苯基-吡咯并异喹啉-3-酮类化合物及其制备方法和应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016248886B2 (en) 2015-04-15 2020-09-10 F. Hoffmann-La Roche Ag Pyridopyrimidinones and their use as NMDA receptor modulators
WO2017100593A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
SI3386591T1 (sl) 2015-12-09 2020-11-30 Cadent Therapeutics, Inc. Heteroaromatski NMDA receptorski modulatorji in njihove uporabe
WO2017109709A2 (en) 2015-12-22 2017-06-29 Novartis Ag A high-throughput assay method for identifying allosteric nmda receptor modulators
ES2975336T3 (es) * 2016-12-22 2024-07-04 Novartis Ag Moduladores del receptor NMDA y usos de los mismos
JOP20210020A1 (ar) 2018-08-03 2021-01-25 Cadent Therapeutics Inc معدلات عطرية غير متجانسة لمستقبل nmda واستخداماتها
CN111840296B (zh) * 2020-07-22 2021-05-04 华中农业大学 一种5H-噻唑并[3,2-a]嘧啶-5-酮类化合物在制备单胺氧化酶抑制剂中的用途
EP4032896A1 (en) * 2021-01-20 2022-07-27 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof
CN112724157B (zh) * 2021-01-23 2022-04-19 中国科学院新疆理化技术研究所 二氢噁唑并[5,4-d]吡咯并[1,2-a]嘧啶-9(5H)-酮类衍生物及用途
US20250073242A1 (en) * 2021-07-30 2025-03-06 The Regents Of The University Of California Slc26a3 inhibitors and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007077490A2 (en) * 2006-01-05 2007-07-12 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888983A (en) * 1970-08-14 1975-06-10 Seperic Derivatives of thiazolino-pyrimidin-6-ones, in inducing analgesia
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
ATE214704T1 (de) 1997-07-18 2002-04-15 Hoffmann La Roche 5h-thiazolo(3,2-a)pyrimidinderivate
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2007006175A1 (en) 2005-07-11 2007-01-18 Zte Corporation Method for implementing channel shared ring protection supported easy failure prevention
JP6130061B2 (ja) 2013-06-19 2017-05-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ インドリン−２−オン又はピロロ−ピリジン／ピリミジン−２−オン誘導体
AU2016248886B2 (en) 2015-04-15 2020-09-10 F. Hoffmann-La Roche Ag Pyridopyrimidinones and their use as NMDA receptor modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007077490A2 (en) * 2006-01-05 2007-07-12 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHUANGXING GUO ET AL.: "Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112094267A (zh) * 2020-08-14 2020-12-18 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 1-苯基-吡咯并异喹啉-3-酮类化合物及其制备方法和应用

Also Published As

Publication number Publication date
HUE040651T2 (hu) 2019-03-28
CN105612162B (zh) 2018-08-21
WO2015052226A1 (en) 2015-04-16
ES2690355T3 (es) 2018-11-20
LT3055315T (lt) 2018-10-25
US9988400B2 (en) 2018-06-05
HK1220202A1 (zh) 2017-04-28
EP3415519A1 (en) 2018-12-19
BR112016007563B1 (pt) 2022-12-20
HRP20181596T1 (hr) 2018-12-14
MX2016004540A (es) 2016-07-21
PT3055315T (pt) 2018-10-25
EP3055315B1 (en) 2018-07-25
CN105612162A (zh) 2016-05-25
JP2019023217A (ja) 2019-02-14
RU2703273C2 (ru) 2019-10-16
US20160222033A1 (en) 2016-08-04
US20180244694A1 (en) 2018-08-30
RU2016115487A3 (enExample) 2018-06-21
CA2926830C (en) 2023-08-01
EP3055315A1 (en) 2016-08-17
JP2016532669A (ja) 2016-10-20
DK3055315T3 (en) 2018-10-22
KR20160068898A (ko) 2016-06-15
BR112016007563A2 (pt) 2020-04-28
PL3055315T3 (pl) 2018-12-31
US10647731B2 (en) 2020-05-12
RS58047B1 (sr) 2019-02-28
SI3055315T1 (sl) 2018-11-30
CA2926830A1 (en) 2015-04-16
RU2016115487A (ru) 2017-11-16
JP6419800B2 (ja) 2018-11-07
KR102361108B1 (ko) 2022-02-10

Similar Documents

Publication Publication Date Title
CN108929336A (zh) 作为nmda受体活性的调节剂的噻唑并嘧啶酮类
JP7664947B2 (ja) Ｉｌ－１７の調節因子としてのイミダゾリダジン
CN105916855B (zh) 作为酪蛋白激酶1d/e抑制剂的取代的4，5，6，7-四氢吡唑并[1，5-a]吡嗪衍生物
TWI736517B (zh) 作為抗癌劑之新穎三環化合物
CN106170489B (zh) 新的吡唑并嘧啶衍生物及其作为malt1抑制剂的用途
CN110167935B (zh) 作为αV整合素抑制剂的3-经取代的丙酸
CN105828820B (zh) 布罗莫结构域抑制剂
CN106986867B (zh) 作为pi3k抑制剂的杂环基胺
CN111484477A (zh) 一种苯并吡啶酮杂环化合物及其用途
WO2023179629A1 (zh) 取代桥环类抑制剂及其制备方法和应用
CN110511209A (zh) 可用作激酶抑制剂的吲哚甲酰胺化合物
TW201412721A (zh) １，４－雙取代嗒□類似物及ｓｍｎ缺乏相關病況之治療方式
CN105658653A (zh) 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
TW201922721A (zh) 化學化合物
CN111032641A (zh) 经取代的5-氰基吲哚化合物及其用途
JP6847851B2 (ja) Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用
TW202016116A (zh) 作為a2a受體拮抗劑的吡唑並三唑並嘧啶衍生物
AU2021276623A1 (en) 3-((1H-pyrazol-4-yl)methyl)-6'-(phenyl)-2H-(1,2'-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression
CN105829316B (zh) 作为RORγ抑制剂的四氢-四唑并[1，5-a]吡嗪
CN115916341A (zh) 用于治疗hbv的吡唑甲酰胺化合物
HK1220202B (zh) 作为nmda受体活性的调节剂的噻唑并嘧啶酮类
TW201410677A (zh) 縮環雜環化合物
TWI613200B (zh) 含氮雜環化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181204

WD01 Invention patent application deemed withdrawn after publication